AbbVie (NYSE: ABBV )
is an odd duck among its large pharma peers, as no company relies more
on a single drug than AbbVie relies on Humira. That should be changing
soon, though, as AbbVie looks to challenge Gilead (NASDAQ: GILD )
in the new market for next-generation hepatitis C (HCV) therapies.
Although I'm bullish on AbbVie's prospects in HCV, I do have some
concerns that the company has under-developed its pipeline and that
Street expectations may already be pretty demanding.
Read the full article here:
AbbVie Inc. Is Closer to Much-Needed Diversification, but Is It Enough?
No comments:
Post a Comment